News | December 14, 2022
JB Pharma to buy Glenmark's ‘Razel’ for Rs. 314 crore in India and Nepal
The acquisition marks JB Pharma’s entry into the ‘Statin’ segment which is the largest group in the cardiac therapy
The acquisition marks JB Pharma’s entry into the ‘Statin’ segment which is the largest group in the cardiac therapy
Move to increase affordability and accessibility for heart failure patients across the country
This product is based on Osmotic Controlled Release Oral Delivery System technology
Since FY 2020 till FY 2022, the organisation has reduced energy consumption by 9.2%
The #Heart2HeartChallengeIndia campaign is very simple – you have to climb 60 steps in a minute, make a video of it, share it on your social media, tag 5 people, inviting them to take this challenge to check their heart health
Our strategy to drive therapy and brand-focused expansion will continue to show results, especially in the domestic business.
JB Pharma is the fastest growing pharmaceutical company in FY 2021-22 and Q1 of FY 2022-23.
Profit after Tax stood at Rs. 105 crore as compared to Rs. 119 crore on account of higher treasury income in Q1 FY22, non-cash ESOP cost, depreciation on account of acquired brands and finance costs in Q1 FY23
The total covered market size of four brands – Z&D, Pediclory, Pecef & Ezinapi combined is Rs 1800 crores
JB, in its new avatar, emerges as the fastest growing pharmaceuticals company in India
Subscribe To Our Newsletter & Stay Updated
